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Abstract
Background: Heterogeneity of acute respiratory distress syndrome (ARDS) could be reduced by identification of
biomarker-based phenotypes. The set of ARDS biomarkers to prospectively define these phenotypes remains to be
established.
Objective: To provide an overview of the biomarkers that were multivariately associated with ARDS development
or mortality.
Data sources: We performed a systematic search in Embase, MEDLINE, Web of Science, Cochrane CENTRAL, and
Google Scholar from inception until 6 March 2020.
Study selection: Studies assessing biomarkers for ARDS development in critically ill patients at risk for ARDS and
mortality due to ARDS adjusted in multivariate analyses were included.
Data extraction and synthesis: We included 35 studies for ARDS development (10,667 patients at risk for ARDS)
and 53 for ARDS mortality (15,344 patients with ARDS). These studies were too heterogeneous to be used in a
meta-analysis, as time until outcome and the variables used in the multivariate analyses varied widely between
studies. After qualitative inspection, high plasma levels of angiopoeitin-2 and receptor for advanced glycation end
products (RAGE) were associated with an increased risk of ARDS development. None of the biomarkers (plasma
angiopoeitin-2, C-reactive protein, interleukin-8, RAGE, surfactant protein D, and Von Willebrand factor) was clearly
associated with mortality.
Conclusions: Biomarker data reporting and variables used in multivariate analyses differed greatly between studies.
Angiopoeitin-2 and RAGE in plasma were positively associated with increased risk of ARDS development. None of
the biomarkers independently predicted mortality. Therefore, we suggested to structurally investigate a
combination of biomarkers and clinical parameters in order to find more homogeneous ARDS phenotypes.
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Introduction
The acute respiratory distress syndrome (ARDS) is a
major problem in the intensive care unit (ICU) with a
prevalence of 10% and an in-hospital mortality rate of
40% [1, 2]. ARDS pathophysiology is based on a triad of
alveolar-capillary membrane injury, high permeability al-
veolar oedema, and migration of inflammatory cells [3].
This triad is not routinely measured in clinical practice.
Therefore, arterial hypoxemia and bilateral opacities on
chest imaging following various clinical insults are used
as clinical surrogates in the American European Consen-
sus Conference (AECC) definition and the newer Berlin
definition of ARDS [4, 5].
Histologically, ARDS is characterized by diffuse alveo-
lar damage (DAD). The correlation between a clinical
and histological diagnosis of ARDS is poor [6]. Only half
of clinically diagnosed patients with ARDS have histo-
logical signs of DAD at autopsy [7–10]. The number of
risk factors for ARDS and consequently the heteroge-
neous histological substrates found in patients with clin-
ical ARDS have been recognized as a major contributor
to the negative randomized controlled trial results
among patients with ARDS [11].
It has been suggested that the addition of biomarkers
to the clinical definition of ARDS could reduce ARDS
heterogeneity by the identification of subgroups [12–15].
A retrospective latent class analysis of large randomized
controlled trials identified two ARDS phenotypes largely
based on ARDS biomarkers combined with clinical pa-
rameters [16, 17]. These phenotypes responded differ-
ently to the randomly assigned intervention arms.
Prospective studies are required to validate these ARDS
phenotypes and their response to interventions. The set
of ARDS biomarkers to prospectively define these phe-
notypes remains to be established.
Numerous biomarkers and their pathophysiological
role in ARDS have been described [12, 18]. In an earlier
meta-analysis, biomarkers for ARDS development and
mortality were examined in univariate analysis [19].
However, pooling of univariate biomarker data may re-
sult in overestimation of the actual effect. For this rea-
son, we conducted a systematic review and included all
biomarkers that were multivariately associated with
ARDS development or mortality. This study provides a
synopsis of ARDS biomarkers that could be used for fu-
ture research in the identification of ARDS phenotypes.
Methods
This systematic review was prospectively registered in
PROSPERO International Prospective Register of System-
atic Reviews (PROSPERO identifier CRD42017078957)
and performed according to the Transparent Reporting of
Systematic Reviews and Meta-analyses (PRISMA) State-
ment [20]. After the search strategy, two reviewers (PZ,
PS, and/or WG) separately performed study eligibility cri-
teria, data extraction, and quality assessment. Any discrep-
ancies were resolved by consensus, and if necessary, a
third reviewer was consulted.
We searched for studies that included biomarkers that
were associated with ARDS development in critically ill
patients at risk for ARDS and mortality in the ARDS
population in multivariate analyses adjusted for back-
ground characteristics. We did not perform a meta-
analysis, because the raw data in all studies was either
not transformed or log transformed resulting in varying
risk ratios and confidence intervals. In addition, the ma-
jority of studies used different biomarker concentration
cut-offs, resulting in varying concentration increments
for risk ratios. Lastly, the number of days until mortality
and variables used in multivariate analysis differed be-
tween studies. For these reasons, we limited this study to
a systematic review, as the multivariate odds ratios were
not comparable and pooling would result in non-
informative estimates [21].
Search strategy
We performed a systematic search in Embase, MED-
LINE, Web of Science, Cochrane CENTRAL, and Goo-
gle Scholar from inception until 30 July 2018 with
assistance from the Erasmus MC librarian. The search
was later updated to 6 March 2020. A detailed descrip-
tion of the systematic search string is presented in Add-
itional file 1. In addition, the reference lists of included
studies and recent systematic reviews were screened to
identify additional eligible studies.
Study eligibility criteria
All retrieved studies were screened on the basis of title
and abstract. Studies that did not contain adult patients
at risk for ARDS or with ARDS and any biomarker for
ARDS were excluded. The following eligibility criteria
were used: human research, adult population, studies in
which biomarkers were presented as odds ratios (OR) or
risk ratios in multivariate analysis with ARDS develop-
ment or mortality as outcome of interest, peer-reviewed
literature only, and English language. Studies comparing
ARDS with healthy control subjects, case series (< 10 pa-
tients included in the study), and studies presenting gene
expression fold change were excluded.
Data extraction
A standardized form was used for data extraction from
all eligible studies. Two clinical endpoints were evalu-
ated in this study: development of ARDS in the at-risk
population (patients that did develop ARDS versus crit-
ically ill patients that did not) and mortality in the ARDS
population (survivors versus non-survivors). The follow-
ing data were extracted: study design and setting, study
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population, sample size, the definition of ARDS used in
the study, outcome, risk ratio with 95% confidence inter-
val in multivariate analyses, and the variables used in the
analyses. In addition, the role of the biomarker in ARDS
pathophysiology as reported by the studies was extracted
and divided into the following categories: increased
endothelial permeability, alveolar epithelial injury, oxida-
tive injury, inflammation, pro-fibrotic, myocardial strain,
coagulation, and others. Subsequently, the relative fre-
quency distribution of biomarker roles in ARDS patho-
physiology was depicted in a bar chart.
Quality assessment
Methodological quality of the included studies was
assessed with the Newcastle-Ottawa Scale (NOS) for
assessing the quality of nonrandomized studies in sys-
tematic reviews and meta-analyses [22]. Items regarding
patient selection, comparability, and outcome were
assessed using a descriptive approach, and a risk-of-bias
score, varying between 0 (high risk) and 9 (low risk), was
assigned to each study.
Results
Literature search and study selection
A total of 8125 articles were identified by the initial
search and 972 by the updated search (Fig. 1). After re-
moval of duplicates and reviewing titles and abstracts,
we selected 438 articles for full-text review. A total of 86
studies was eligible for data extraction: 35 for ARDS de-
velopment and 53 for ARDS mortality.
Study characteristics and quality assessment
The study characteristics of the 35 studies for ARDS de-
velopment are presented in Table 1. A total of 10,667
critically ill patients was at risk for ARDS, of whom 2419
(24.6%) patients developed ARDS. The majority of
Fig. 1 PRISMA flow diagram for a systematic search
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Table 3 Risk ratios for ARDS development in the at-risk population
Reference Biomarker role in ARDS Sample
size
Risk ratio
(95% CI)
Cut-off Comment
Biomarkers in plasma
Adiponectin Palakshappa
2016 [48]
Anti-inflammatory 163 1.12
(1.01–1.25)
Per 5 mcg/mL
Angiopoietin-2 Agrawal 2013
[23]
Increased endothelial
permeability
167 1.8
(1.0–3.4)
Per log10
Angiopoietin-2 Fremont 2010
[32]
Increased endothelial
permeability
192 2.20
(1.19–4.05)
Highest vs lowest
quartile
Angiopoietin-2 Reilly 2018 [49] Increased endothelial
permeability
703 1.49
(1.20–1.77)
Per log increase
Angiopoietin-2 Ware 2017 [54] Increased endothelial
permeability
393 1.890
(1.322–2.702)
1st vs 4th quartile
Angiopoietin-2 Xu 2018 [55] Increased endothelial
permeability
158 1.258
(1.137–1.392)
Advanced oxidant protein
products
Du 2016 [30] Oxidative injury 70 1.164
(1.068–1.269)
Brain natriuretic peptide Fremont 2010
[32]
Myocardial strain 192 0.45
(0.26–0.77)
Highest vs lowest
quartile
Brain natriuretic peptide Komiya 2011
[40]
Myocardial strain 124 14.425
(4.382–47.483)
> 500 pg/mL Outcome is
CPE
Club cell secretory protein Jensen 2016
[38]
Alveolar epithelial injury 405 2.6
(0.7–9.7)
≥ 42.8 ng/mL Learning
cohort
Club cell secretory protein Jensen 2016
[38]
Alveolar epithelial injury 353 0.96
(0.20–4.5)
≥ 42.8 ng/mL Validating
cohort
Club cell secretory protein Lin 2017 [42] Alveolar epithelial injury 212 1.096
(1.085–1.162)
C-reactive protein (CRP) Bai 2018 [28] Inflammation 384 1.314
(0.620–1.603)
C-reactive protein (CRP) Chen 2019 [29] Inflammation 115 0.994
(0.978–1.010)
C-reactive protein (CRP) Huang 2019
[35]
Inflammation 152 1.287
(0.295–5.606)
≥ 90.3 mg/L
C-reactive protein (CRP) Huang 2019
[36]
Inflammation 1933 1.008
(1.007–1.010)
C-reactive protein (CRP) Komiya 2011
[40]
Inflammation 124 0.106
(0.035–0.323)
> 50 mg/L Outcome is
CPE
C-reactive protein (CRP) Lin 2017 [42] Inflammation 212 1.007
(1.001–1.014)
C-reactive protein (CRP) Osaka 2011
[47]
Inflammation 27 1.029
(0.829–1.293)
Per 1 mg/dL
increase
C-reactive protein (CRP) Wang 2019 [53] Inflammation 109 1.000
(0.992–1.008)
C-reactive protein (CRP) Ying 2019 [57] Inflammation 145 1.22
(0.95–1.68)
Free 2-chlorofatty acid Meyer 2017
[45]
Oxidative injury 198 1.62
(1.25–2.09)
Per log10
Total 2-chlorofatty acid Meyer 2017
[45]
Oxidative injury 198 1.82
(1.32–2.52)
Per log10
Free 2-chlorostearic acid Meyer 2017
[45]
Oxidative injury 198 1.82
(1.41–2.37)
Per log10
Total 2-chlorostearic acid Meyer 2017
[45]
Oxidative injury 198 1.78
(1.31–2.43)
Per log10
Endocan Gaudet 2018
[33]
Leukocyte adhesion inhibition 72 0.001
(0–0.215)
> 5.36 ng/mL
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Table 3 Risk ratios for ARDS development in the at-risk population (Continued)
Reference Biomarker role in ARDS Sample
size
Risk ratio
(95% CI)
Cut-off Comment
Endocan Mikkelsen 2012
[46]
Leukocyte adhesion inhibition 48 0.69
(0.49–0.97)
1 unit increase
Endocan Ying 2019 [57] Leukocyte adhesion
modulation
145 1.57
(1.14–2.25)
Fibrinogen Luo 2017 [44] Coagulation 157 1.893
(1.141–3.142)
Glutamate Bai 2017 [27] Non-essential amino acid,
neurotransmitter
50 2.229
(1.082–2.634)
Glutamate Bai 2017 [27] Non-essential amino acid,
neurotransmitter
42 0.996
(0.965–1.028)
Glutamate Bai 2018 [28] Non-essential amino acid 384 3.022
(2.001–4.043)
Growth arrest-specific gene 6 Yeh 2017 [56] Endothelial activation 129 1.6
(1.3–2.6)
Insulin-like growth factor 1 Ahasic 2012
[24]
Pro-fibrotic 531 0.58
(0.42–0.79)
Per log10
IGF binding protein 3 Ahasic 2012
[24]
Pro-fibrotic 531 0.57
(0.40–0.81)
Per log10
Interleukin-1 beta Aisiku 2016 [25] Pro-inflammatory 194 0.98
(0.73–1.32)
Interleukin-1 beta Chen 2019 [29] Pro-inflammatory 115 1.001
(0.945–1.061)
Interleukin-1 beta Huang 2019
[35]
Pro-inflammatory 152 0.666
(0.152–2.910)
≥ 11.3 pg/mL
Interleukin-1 beta Wang 2019 [53] Pro-inflammatory 109 1.021
(0.982–1.063)
Interleukin-6 Aisiku 2016 [25] Pro-inflammatory 195 1.24
(1.05–1.49)
Interleukin-6 Bai 2018 [28] Pro-inflammatory 384 1.194
(0.806–1.364)
Interleukin-6 Chen 2019 [29] Pro-inflammatory 115 0.998
(0.993–1.003)
Interleukin-6 Huang 2019
[35]
Pro-inflammatory 152 0.512
(0.156–1.678)
≥ 63.7 pg/mL
Interleukin-6 Yeh 2017 [56] Pro-inflammatory 129 1.4
(0.98–1.7)
Interleukin-8 Agrawal 2013
[23]
Pro-inflammatory 167 1.3
(0.97–1.8)
Per log10
Interleukin-8 Aisiku 2016 [25] Pro-inflammatory 194 1.26
(1.04–1.53)
Interleukin-8 Chen 2019 [29] Pro-inflammatory 115 1.000
(0.996–1.003)
Interleukin-8 Fremont 2010
[32]
Pro-inflammatory 192 1.81
(1.03–3.17)
Highest vs lowest
quartile
Interleukin-8 Liu 2017 [43] Pro-inflammatory 134 1.4
(0.98–1.7)
Per log10
Interleukin-8 Yeh 2017 [56] Pro-inflammatory 129 1.4
(0.92–1.7)
Interleukin-10 Aisiku 2016 [25] Anti-inflammatory 195 1.66
(1.22–2.26)
Interleukin-10 Chen 2019 [29] Anti-inflammatory 115 1.003
(0.998–1.018)
Interleukin-10 Fremont 2010 Anti-inflammatory 192 2.02 Highest vs lowest
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Table 3 Risk ratios for ARDS development in the at-risk population (Continued)
Reference Biomarker role in ARDS Sample
size
Risk ratio
(95% CI)
Cut-off Comment
[32] (0.96–4.25) quartile
Interleukin-12p70 Aisiku 2016 [25] Pro-inflammatory 194 1.18
(0.82–1.69)
Interleukin-17 Chen 2019 [29] Pro-inflammatory 115 1.003
(1.000–1.007)
Not
significant
Interleukin-17 Huang 2019
[35]
Pro-inflammatory 152 0.644
(0.173–2.405)
≥ 144.55 pg/mL
Interleukin-17 Wang 2019 [53] Pro-inflammatory 109 1.001
(0.997–1.004)
Leukotriene B4 Amat 2000 [26] Pro-inflammatory 35 14.3
(2.3–88.8)
> 14 pmol/mL
Microparticles Shaver 2017
[51]
Coagulation 280 0.693
(0.490–0.980)
Per 10 μM
Mitochondrial DNA Faust 2020 [31] Damage-associated molecular
pattern
224 1.58
(1.14–2.19)
48 h plasma
Mitochondrial DNA Faust 2020 [31] Damage-associated molecular
pattern
120 1.52
(1.12–2.06)
Per log copies per
microlitre
48 h plasma
Myeloperoxidase Meyer 2017
[45]
Pro-inflammatory 198 1.28
(0.89–1.84)
Per log10
Nitric oxide Aisiku 2016 [25] Oxidative injury 193 1.60
(0.98–2.90)
Parkinson disease 7 Liu 2017 [43] Anti-oxidative injury 134 1.8
(1.1–3.5)
Per log10
Pre B cell colony enhancing factor Lee 2011 [41] Pro-inflammatory 113 0.78
(0.43–1.41)
Per 10 fold increase
Procalcitonin Bai 2018 [28] Inflammation 384 1.156
(0.844–1.133)
Procalcitonin Chen 2019 [29] Inflammation 115 1.020
(0.966–1.077)
Procalcitonin Huang 2019
[35]
Inflammation 152 2.506
(0.705–8.913)
≥ 13.2 ng/mL
Procalcitonin Huang 2019
[36]
Inflammation 1933 1.008
(1.000–1.016)
Not
significant
Procalcitonin Wang 2019 [53] Inflammation 109 1.019
(0.981–1.058)
Procollagen III Fremont 2010
[32]
Pro-fibrotic 192 2.90
(1.61–5.23)
Highest vs lowest
quartile
Receptor for advanced glycation
end products
Fremont 2010
[32]
Alveolar epithelial injury 192 3.33
(1.85–5.99)
Highest vs lowest
quartile
Receptor for advanced glycation
end products
Jabaudon 2018
[37]
Alveolar epithelial injury 464 2.25
(1.60–3.16)
Per log10 Baseline
Receptor for advanced glycation
end products
Jabaudon 2018
[37]
Alveolar epithelial injury 464 4.33
(2.85–6.56)
Per log10 Day 1
Receptor for advanced glycation
end products
Jones 2020 [39] Alveolar epithelial injury 672 1.73
(1.35–2.21)
European
ancestry
Receptor for advanced glycation
end products
Jones 2020 [39] Alveolar epithelial injury 672 2.05
(1.50–2.83)
African
ancestry
Receptor for advanced glycation
end products
Jones 2020 [39] Alveolar epithelial injury 843 2.56
(2.14–3.06)
European
ancestry
Receptor for advanced glycation
end products
Ware 2017 [54] Alveolar epithelial injury 393 2.382
(1.638–3.464)
1st vs 4th quartile
Receptor interacting protein
kinase-3
Shashaty 2019
[50]
Increased endothelial
permeability
120 1.30
(1.03–1.63)
Per 0.5 SD
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studies used the Berlin definition of ARDS (21/35),
followed by the AECC criteria of ARDS (13/35). The in-
cluded biomarkers were measured in plasma, cerebro-
spinal fluid, and bronchoalveolar lavage fluid. In all
studies, the first sample was taken within 72 h following
ICU admission.
The study characteristics of the 53 studies for ARDS
mortality are presented in Table 2. A total of 15,344
patients with ARDS were included with an observed
mortality rate of 36.0%. The AECC definition of ARDS
was used in the majority of included studies (39/53).
The included biomarkers were measured in plasma,
bronchoalveolar lavage fluid, and urine. All samples were
taken within 72 h following the development of ARDS.
The median quality of the included publications ac-
cording to the NOS was 7 (range 4–9) for ARDS
Table 3 Risk ratios for ARDS development in the at-risk population (Continued)
Reference Biomarker role in ARDS Sample
size
Risk ratio
(95% CI)
Cut-off Comment
Receptor interacting protein
kinase-3
Shashaty 2019
[50]
Increased endothelial
permeability
180 1.83
(1.35–2.48)
Per 0.5 SD
Soluble endothelial selectin Osaka 2011
[47]
Pro-inflammatory 27 1.099
(1.012–1.260)
Per 1 ng/mL
increase
Soluble urokinase plasminogen
activator receptor
Chen 2019 [29] Pro-inflammatory 115 1.131
(1.002–1.277)
Surfactant protein D Jensen 2016
[38]
Alveolar epithelial injury 405 3.4
(1.0–11.4)
≥ 525.6 ng/mL Learning
cohort
Surfactant protein D Jensen 2016
[38]
Alveolar epithelial injury 353 8.4
(2.0–35.4)
≥ 525.6 ng/mL Validating
cohort
Surfactant protein D Suzuki 2017
[52]
Alveolar epithelial injury 68 5.31
(1.40–20.15)
Per log10
Tissue inhibitor of matrix
metalloproteinase 3
Hendrickson
2018 [34]
Decreases endothelial
permeability
182 1.4
(1.0–2.0)
1 SD increase
Tumour necrosis factor alpha Aisiku 2016 [25] Pro-inflammatory 195 1.03
(0.71–1.51)
Tumour necrosis factor alpha Chen 2019 [29] Pro-inflammatory 115 1.002
(0.996–1.009)
Tumour necrosis factor alpha Fremont 2010
[32]
Pro-inflammatory 192 0.51
(0.27–0.98)
Highest vs lowest
quartile
Tumour necrosis factor alpha Huang 2019
[35]
Pro-inflammatory 152 3.999
(0.921–17.375)
≥ 173.0 pg/mL
Tumour necrosis factor alpha Wang 2019 [53] Pro-inflammatory 109 1.000
(0.995–1.005)
Biomarkers in CSF
Interleukin-1 beta Aisiku 2016 [25] Pro-inflammatory 174 1.11
(0.80–1.54)
Interleukin-6 Aisiku 2016 [25] Pro-inflammatory 174 1.06
(0.95–1.19)
Interleukin-8 Aisiku 2016 [25] Pro-inflammatory 173 1.01
(0.92–1.12)
Interleukin-10 Aisiku 2016 [25] Anti-inflammatory 174 1.33
(1.00–1.76)
Interleukin-12p70 Aisiku 2016 [25] Pro-inflammatory 173 1.52
(1.04–2.21)
Nitric oxide Aisiku 2016 [25] Oxidative injury 172 1.66
(0.70–3.97)
Tumour necrosis factor alpha Aisiku 2016 [25] Pro-inflammatory 174 1.43
(0.97–2.14)
Biomarkers in BALF
Soluble trombomodulin Suzuki 2017
[52]
Endothelial injury 68 7.48
(1.60–34.98)
Abbreviations: CPE cardiopulmonary effusion, CSF cerebrospinal fluid, BALF bronchoalveolar lavage fluid, SD standard deviation
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development and 8 (range 5–9) for ARDS mortality
(Additional file 2).
Biomarkers associated with ARDS development in the at-
risk population
A total of 37 biomarkers in plasma, 7 in cerebrospinal
fluid, and 1 in bronchoalveolar lavage fluid were assessed
in multivariate analyses (Table 3). Five studies examined
angiopoeitin-2 (Ang-2) and seven studies examined re-
ceptor for advanced glycation end products (RAGE). In
all studies, high plasma levels of Ang-2 and RAGE were
significantly associated with an increased risk of ARDS
development in the at-risk population. Similar results
were seen for surfactant protein D (SpD) in plasma in all
three studies that assessed SpD. In contrast, biomarkers
for inflammation as C-reactive protein (CRP), procalcito-
nin, interleukin-6, and interleukin-8 were not clearly as-
sociated with ARDS development. The majority of
biomarkers in plasma are surrogates for inflammation in
ARDS pathophysiology (Fig. 2).
Biomarkers associated with mortality in the ARDS
population
A total of 49 biomarkers in plasma, 8 in bronchoalveolar
lavage fluid, and 3 in urine were included in this study
(Table 4). Ang-2, CRP, interleukin-8 (IL-8), RAGE, SpD,
and Von Willebrand factor (VWF) in plasma were
assessed in four or more studies. However, none of these
biomarkers was associated with ARDS mortality in all
four studies. Similarly to biomarkers in ARDS develop-
ment, the majority of biomarkers for ARDS mortality in
plasma had a pathophysiological role in inflammation
(Fig. 2). The majority of biomarkers measured in
bronchoalveolar lavage fluid had a pro-fibrotic role in
ARDS pathophysiology.
Discussion
In the current systematic review, we present a synopsis
of biomarkers for ARDS development and mortality
tested in multivariate analyses. We did not perform a
meta-analysis because of severe data heterogeneity be-
tween studies. Upon qualitative inspection, we found
that high levels of Ang-2 and RAGE were associated
with ARDS development in the at-risk population. None
of the biomarkers assessed in four or more studies was
associated with an increased mortality rate in all studies.
The majority of plasma biomarkers for both ARDS de-
velopment and mortality are surrogates for inflammation
in ARDS pathophysiology.
Previously, Terpstra et al. [19] calculated univariate
ORs from absolute biomarker concentrations and per-
formed a meta-analysis. They found that 12 biomarkers
in plasma were associated with mortality in patients with
ARDS. However, a major limitation of their meta-
analysis is that these biomarkers were tested in univari-
ate analyses without considering confounders as disease
severity scores. Given the high univariate ORs as com-
pared to the multivariate ORs found in this systematic
review, the performance of these biomarkers is likely to
be overestimated. Jabaudon et al. [109] found in an indi-
vidual patient data meta-analysis that high concentra-
tions of plasma RAGE were associated with 90-day
mortality independent of driving pressure or tidal
volume. However, they could not correct for disease se-
verity score as these differed between studies. Unfortu-
nately, we were unable to perform a meta-analysis on
Fig. 2 Biomarker role in ARDS pathophysiology
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Table 4 Risk ratios for ARDS mortality in the ARDS population
Reference Biomarker role in ARDS Sample
size
Risk ratio
(95% CI)
Cut-off Comment
Biomarkers in plasma
Activin-A Kim 2019 [76] Pro-fibrotic 97 2.64
(1.04–6.70)
Angiopoietin-1/angiopoietin-2 ratio Ong 2010
[90]
Modulates endothelial
permeability
24 5.52
(1.22–24.9)
Angiopoietin-2 Calfee 2012
[65]
Increased endothelial
permeability
931 0.92
(0.73–1.16)
Per log10 Infection-
related ALI
Angiopoietin-2 Calfee 2012
[65]
Increased endothelial
permeability
931 1.94
(1.15–3.25)
Per log10 Noninfection-
related ALI
Angiopoietin-2 Calfee 2015
[66]
Increased endothelial
permeability
100 2.54
(1.38–4.68)
Per log10 Single centre
Angiopoietin-2 Calfee 2015
[66]
Increased endothelial
permeability
853 1.43
(1.19–1.73)
per log10 Multicentre
Angiotensin 1–9 Reddy 2019
[95]
Pro-fibrotic 39 2.24
(1.15–4.39)
Concentration
doubled (in Ln)
Angiotensin 1–10 Reddy 2019
[95]
Pro-fibrotic 39 0.36
(0.18–0.72)
Concentration
doubled (in Ln)
Angiotensin converting enzyme Tsantes 2013
[103]
Endothelial permeability,
pro-fibrotic
69 1.06
(1.02–1.10)
Per 1 unit increase 28-day
mortality
Angiotensin converting enzyme Tsantes 2013
[103]
Endothelial permeability,
pro-fibrotic
69 1.04
(1.01–1.07)
Per 1 unit increase 90-day
mortality
NT-pro brain natriuretic peptide Bajwa 2008
[59]
Myocardial strain 177 2.36
(1.11–4.99)
≥ 6813 ng/L
NT-pro brain natriuretic peptide Lin 2012 [81] Myocardial strain 87 2.18
(1.54–4.46)
Per unit
Club cell secretory protein Cartin-Ceba
2015 [67]
Alveolar epithelial injury 100 1.09
(0.60–2.02)
Per log10
Club cell secretory protein Lesur 2006
[78]
Alveolar epithelial injury 78 1.37
(1.25–1.83)
Increments of 0.5
Copeptin Lin 2012 [81] Osmo-regulatory 87 4.72
(2.48–7.16)
Per unit
C-reactive protein (CRP) Adamzik
2013 [58]
Inflammation 47 1.01
(0.9–1.1)
Per log10
C-reactive protein (CRP) Bajwa 2009
[60]
Inflammation 177 0.67
(0.52–0.87)
Per log10
C-reactive protein (CRP) Lin 2010 [80] Inflammation 63 2.316
(0.652–8.226)
C-reactive protein (CRP) Tseng 2014
[104]
Inflammation 56 1.265
(0.798–2.005)
Day 3
D-dimer Tseng 2014
[104]
Coagulation 56 1.211
(0.818–1.793)
Decoy receptor 3 Chen 2009
[68]
Immunomodulation 59 4.02
(1.20–13.52)
> 1 ng/mL Validation
cohort
Endocan Tang 2014
[100]
Leukocyte adhesion
inhibition
42 1.374
(1.150–1.641)
> 4.96 ng/mL
Endocan Tsangaris
2017 [102]
Leukocyte adhesion
inhibition
53 3.36
(0.74–15.31)
> 13 ng/mL
Galectin 3 Xu 2017 [108] Pro-fibrotic 63 1.002
(0.978–1.029)
Per 1 ng/mL
Granulocyte colony stimulating
factor
Suratt 2009
[99]
Inflammation 645 1.70
(1.06–2.75)
Quartile 4 vs
quartile 2
Growth differentiation factor-15 Clark 2013
[70]
Pro-fibrotic 400 2.86
(1.84–4.54)
Per log10
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Table 4 Risk ratios for ARDS mortality in the ARDS population (Continued)
Reference Biomarker role in ARDS Sample
size
Risk ratio
(95% CI)
Cut-off Comment
Heparin binding protein Lin 2013 [82] Inflammation, endothelial
permeability
78 1.52
(1.12–2.85)
Per log10
High mobility group protein B1 Tseng 2014
[104]
Pro-inflammatory 56 1.002
(1.000–1.004)
Day 1
High mobility group protein B1 Tseng 2014
[104]
Pro-inflammatory 56 0.990
(0.968–1.013)
Day 3
Insulin-like growth factor Ahasic 2012
[24]
Pro-fibrotic 175 0.70
(0.51–0.95)
Per log10
IGF binding protein 3 Ahasic 2012
[24]
Pro-fibrotic 175 0.69
(0.50–0.94)
Per log10
Intercellular adhesion molecule-1 Calfee 2009
[63]
Pro-inflammatory 778 1.22
(0.99–1.49)
Per log10
Intercellular adhesion molecule-1 Calfee 2011
[64]
Pro-inflammatory 547 0.74
(0.59–0.95)
Per natural log
Intercellular adhesion molecule-1 McClintock
2008 [86]
Pro-inflammatory 50 5.8
(1.1–30.0)
Per natural log
Interleukin-1 beta Lin 2010 [80] Pro-inflammatory 63 1.355
(0.357–5.140)
Per log 10
Interleukin-6 Calfee 2015
[66]
Pro-inflammatory 100 1.81
(1.34–2.45)
Per log10 Single centre
Interleukin-6 Calfee 2015
[66]
Pro-inflammatory 853 1.24
(1.14–1.35)
Per log10 Multicentre
Interleukin-6 Parsons 2005
[92]
Pro-inflammatory 781 1.18
(0.93–1.49)
Per log10
Interleukin-8 Amat 2000
[26]
Pro-inflammatory 21 0.09
(0.01–1.35)
> 150 pg/mL
Interleukin-8 Calfee 2011
[64]
Pro-inflammatory 547 1.36
(1.15–1.62)
Per natural log
Interleukin-8 Calfee 2015
[66]
Pro-inflammatory 100 1.65
(1.25–2.17)
Per log10 Single centre
Interleukin-8 Calfee 2015
[66]
Pro-inflammatory 853 1.41
(1.27–1.57)
Per log10 Multicentre
Interleukin-8 Cartin-Ceba
2015 [67]
Pro-inflammatory 100 1.08
(0.72–1.61)
Per log10
Interleukin-8 Lin 2010 [80] Pro-inflammatory 63 0.935
(0.280–3.114)
Per log 10
Interleukin-8 McClintock
2008 [86]
Pro-inflammatory 50 2.0
(1.1–4.0)
Per natural log
Interleukin-8 Parsons 2005
[92]
Pro-inflammatory 780 1.73
(1.28–2.34)
Per log10
Interleukin-8 Tseng 2014
[104]
Pro-inflammatory 56 1.039
(0.955–1.130)
Day 1
Interleukin-8 Tseng 2014
[104]
Pro-inflammatory 56 1.075
(0.940–1.229)
Day 3
Interleukin-10 Parsons 2005
[92]
Anti-inflammatory 593 1.23
(0.86–1.76)
Per log10
Interleukin-18 Dolinay 2012
[71]
Pro-inflammatory 28 1.60
(1.17–2.20)
Per 500 pg/mL
increase
Interleukin-18 Rogers 2019
[97]
Pro-inflammatory 683 2.2
(1.5–3.1)
≥ 800 pg/mL
Leukocyte microparticles Guervilly
2011 [75]
Immunomodulation 52 5.26
(1.10–24.99)
< 60 elements/μL
Leukotriene B4 Amat 2000 Pro-inflammatory 21 22.5 > 14 pmol/mL
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Table 4 Risk ratios for ARDS mortality in the ARDS population (Continued)
Reference Biomarker role in ARDS Sample
size
Risk ratio
(95% CI)
Cut-off Comment
[26] (1.1–460.5)
Neutrophil elastase Wang 2017
[105]
Pro-inflammatory 167 1.76
(p value 0.002)
1 SD change Day 1
Neutrophil elastase Wang 2017
[105]
Pro-inflammatory 167 1.58
(p value 0.06)
1 SD change Day 3
Neutrophil elastase Wang 2017
[105]
Pro-inflammatory 167 1.70
(p value 0.001)
1 SD change Day 7
Neutrophil to lymphocyte ratio Li 2019 [79] Pro-inflammatory 224 5.815
(1.824–18.533)
First–fourth quartile
Neutrophil to lymphocyte ratio Wang 2018
[106]
Pro-inflammatory 247 1.011
(1.004–1.017)
Per 1% increase
Neutrophil to lymphocyte ratio Wang 2018
[106]
Pro-inflammatory 247 1.532
(1.095–2.143)
> 14
Nucleated red blood cells Menk 2018
[87]
Erythrocyte progenitor cell,
pro-inflammatory
404 3.21
(1.93–5.35)
> 220/μL
Peptidase inhibitor 3 Wang 2017
[105]
Anti-inflammatory 167 0.50
(p value 0.003)
1 SD change Day 1
Peptidase inhibitor 3 Wang 2017
[105]
Anti-inflammatory 167 0.43
(p value 0.001)
1 SD change Day 3
Peptidase inhibitor 3 Wang 2017
[105]
Anti-inflammatory 167 0.70
(p value 0.18)
1 SD change Day 7
Plasminogen activator inhibitor 1 Cartin-Ceba
2015 [67]
Coagulation 100 0.96
(0.62–1.47)
Per log10
Plasminogen activator inhibitor 1
(activity)
Tsangaris
2009 [101]
Coagulation 52 1.30
(0.84–1.99)
Per 1 unit increase
Procalcitonin Adamzik
2013 [58]
Inflammation 47 1.01
(0.025–1.2)
Per log10
Procalcitonin Rahmel 2018
[94]
Inflammation 119 0.999
(0.998–1.001)
Protein C McClintock
2008 [86]
Coagulation 50 0.5 (0.2–1.0) Per natural log
Protein C Tsangaris
2017 [102]
Coagulation 53 3.58
(0.73–15.54)
< 41.5 mg/dL
Receptor for advanced glycation
end products
Calfee 2008
[62]
Alveolar epithelial injury 676 1.41
(1.12–1.78)
Per log10 Tidal volume
12mL/kg
Receptor for advanced glycation
end products
Calfee 2008
[62]
Alveolar epithelial injury 676 1.03
(0.81–1.31)
Per log10 Tidal volume 6
mL/kg
Receptor for advanced glycation
end products
Calfee 2015
[66]
Alveolar epithelial injury 100 1.98
(1.18–3.33)
Per log10 Single centre
Receptor for advanced glycation
end products
Calfee 2015
[66]
Alveolar epithelial injury 853 1.16
(1.003–1.34)
Per log10 Multicentre
Receptor for advanced glycation
end products
Cartin-Ceba
2015 [67]
Alveolar epithelial injury 100 0.81
(0.50–1.30)
Per log10
Receptor for advanced glycation
end products
Mrozek 2016
[89]
Alveolar epithelial injury 119 3.1
(1.1–8.9)
–
Soluble suppression of
tumourigenicity-2
Bajwa 2013
[61]
Myocardial strain and
inflammation
826 1.47
(0.99–2.20)
≥ 534 ng/mL (day
0)
Day 0
Soluble suppression of
tumourigenicity-2
Bajwa 2013
[61]
Myocardial strain and
inflammation
826 2.94
(2.00–4.33)
≥ 296 ng/mL (day
3)
Day 3
Soluble triggering receptor
expressed on myeloid cells-1
Lin 2010 [80] Pro-inflammatory 63 6.338
(1.607–24.998)
Per log 10
Surfactant protein-A Eisner 2003
[72]
Alveolar epithelial injury 565 0.92
(0.68–1.27)
Per 100 ng/mL
increment
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Table 4 Risk ratios for ARDS mortality in the ARDS population (Continued)
Reference Biomarker role in ARDS Sample
size
Risk ratio
(95% CI)
Cut-off Comment
Surfactant protein D Calfee 2011
[64]
Alveolar epithelial injury 547 1.55
(1.27–1.88)
Per natural log
Surfactant protein D Calfee 2015
[66]
Alveolar epithelial injury 100 1.33
(0.82–2.14)
Per log10 Single centre
Surfactant protein D Calfee 2015
[66]
Alveolar epithelial injury 853 1.09
(0.95–1.24)
Per log10 Multicentre
Surfactant protein D Eisner 2003
[72]
Alveolar epithelial injury 565 1.21
(1.08–1.35)
Per 100 ng/mL
increment
Thrombin–antithrombin III complex Cartin-Ceba
2015 [67]
Coagulation 100 1.05
(0.53–2.05)
Per log10
High sensitivity troponin I Metkus 2017
[88]
Myocardial injury 1057 0.94
(0.64–1.39)
1st, 5th quintile
Cardiac troponin T Rivara 2012
[96]
Myocardial injury 177 1.44
(1.14–1.81)
Per 1 ng/mL
increase
Trombomodulin Sapru 2015
[98]
Coagulation 449 2.40
(1.52–3.83)
Per log10 Day 0
Trombomodulin Sapru 2015
[98]
Coagulation 449 2.80
(1.69–4.66)
Per log10 Day 3
Tumour necrosis factor alpha Lin 2010 [80] Pro-inflammatory 63 3.691
(0.668–20.998)
Per log 10
Tumour necrosis factor receptor-1 Calfee 2011
[64]
Pro-inflammatory 547 1.58
(1.20–2.09)
Per natural log
Tumour necrosis factor receptor-1 Parsons 2005
[91]
Pro-inflammatory 562 5.76
(2.63–12.6)
Per log10
Tumour necrosis factor receptor-2 Parsons 2005
[91]
Pro-inflammatory 376 2.58
(1.05–6.31)
Per log10
Uric acid Lee 2019 [77] Antioxidant 237 0.549
(0.293–1030)
≥ 3.00 mg/dL
Von Willebrand factor Calfee 2011
[64]
Endothelial activation,
coagulation
547 1.57
(1.16–2.12)
Per natural log
Von Willebrand factor Calfee 2012
[65]
Endothelial activation,
coagulation
931 1.51
(1.20–1.90)
Per log10
Von Willebrand factor Calfee 2015
[66]
Endothelial activation,
coagulation
853 1.83
(1.46–2.30)
Per log10 Multicentre
Von Willebrand factor Cartin-Ceba
2015 [67]
Endothelial activation,
coagulation
100 2.93
(0.90–10.7)
Per log10
Von Willebrand factor Ware 2004
[107]
Endothelial activation,
coagulation
559 1.6
(1.4–2.1)
Per SD increment
Biomarkers in BALF
Angiopoietin-2 Tsangaris
2017 [102]
Increased endothelial
permeability
53 11.18
(1.06–117.48)
> 705 pg/mL
Fibrocyte percentage Quesnel 2012
[93]
Pro-fibrotic 92 6.15
(2.78–13.64)
> 6%
Plasminogen activator inhibitor 1
(activity)
Tsangaris
2009 [101]
Coagulation 52 0.37
(0.06–2.35)
Per 1 unit increase
Procollagen III Clark 1995
[69]
Pro-fibrotic 117 3.6
(1.2–10.7)
≥ 1.75 U/mL
Procollagen III Forel 2015
[73]
Pro-fibrotic 51 5.02
(2.06–12.25)
≥ 9 μg/L
Transforming growth factor alpha Madtes 1998
[83]
Pro-fibrotic 74 2.3
(0.7–7.0)
> 1.08 pg/mL
Transforming growth factor beta 1 Forel 2018
[74]
Pro-fibrotic 62 1003
(0.986–1.019)
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multivariate data because of heterogeneity of the in-
cluded studies, as transformation of raw data, biomarker
concentration cut-offs, time until outcome, and the vari-
ables used in the multivariate analyses varied widely be-
tween studies. This could be an incentive to standardize
the presentation of ARDS biomarker research in terms
of statistics and outcome for future analyses or to make
individual patient data accessible.
ARDS biomarkers are presumed to reflect the patho-
physiology of ARDS, characterized by alveolar-capillary
membrane injury, high permeability alveolar oedema,
and migration of inflammatory cells [3]. Previously,
Terpstra et al. [19] proposed that biomarkers for ARDS
development were correlated with alveolar tissue injury,
whereas biomarkers for ARDS mortality correlated more
with inflammation. In this systematic review, we found
that the majority of biomarkers tested for both ARDS
development and mortality were surrogates for inflam-
mation. However, following qualitative inspection, bio-
markers for inflammation were not evidently associated
with either ARDS development or mortality. In contrast,
markers for alveolar epithelial injury (plasma RAGE and
SpD) and endothelial permeability (plasma Ang-2) seem
to be associated with ARDS development. Therefore, we
should consider how we intend to use (a set of) bio-
markers in patients with ARDS.
A biomarker for ARDS development should be specific
for ARDS, i.e. a biomarker that reflects alveolar injury or
alveolar-capillary injury. Half of plasma biomarkers for
ARDS development included in this study reflected in-
flammation. An increase in inflammatory biomarkers is
known to correlate with increased disease severity scores
[71, 97, 110]. In turn, the majority of studies in this re-
view found significantly higher disease severity scores in
the critically ill patients that eventually developed ARDS.
Thus, plasma biomarkers for inflammation rather repre-
sented an estimation of disease severity and its associ-
ated increased risk for the development of ARDS. In
addition, biomarkers for inflammation in plasma lack
the specificity to diagnose ARDS, as they are unlikely to
differentiate sepsis with ARDS from sepsis without
ARDS. In contrast, locally sampled biomarkers for in-
flammation, for example in the alveolar space, could po-
tentially diagnose ARDS [111]. Biomarkers used for
ARDS mortality or for the identification of less heteroge-
neous ARDS phenotypes do not require to be ARDS
specific, provided that they adequately predict or stratify
patients with ARDS.
The heterogeneity of ARDS has been recognized as a
major contributor to the negative randomized controlled
trial results among patients with ARDS [11]. Therefore,
it is necessary to identify homogeneous ARDS pheno-
types that are more likely to respond to an intervention.
This is known as predictive enrichment [112]. Previ-
ously, patients with ARDS have been successfully strati-
fied based on clinical parameters, such as ARDS risk
factor (pulmonary or extra-pulmonary) or PaO2/FiO2 ra-
tio [113]. ARDS biomarkers could be used to stratify pa-
tients with ARDS based on biological or
pathophysiological phenotype. For example, trials of
novel therapies designed to influence vascular perme-
ability may benefit from preferentially enrolling patients
with high Ang-2 concentrations. Recently, clinical pa-
rameters have been combined with a set of biomarkers
in a retrospective latent class analysis. In three trials, two
distinct phenotypes were found: hyperinflammatory and
hypoinflammatory ARDS [16, 17]. Patients with the
hyperinflammatory phenotype had reduced mortality
rate with higher positive end-expiratory pressures and
with liberal fluid treatment, whereas the trials them-
selves found no difference between the entire interven-
tion groups. The next step is to validate the
identification of ARDS phenotypes based on latent class
analysis in prospective studies. An adequate combination
of biomarkers and clinical parameters remains to be
established. Until now, there is no list of biomarkers that
are associated with ARDS development or mortality in-
dependently of clinical parameters. This systematic re-
view may guide the selection of ARDS biomarkers used
for predictive enrichment.
Table 4 Risk ratios for ARDS mortality in the ARDS population (Continued)
Reference Biomarker role in ARDS Sample
size
Risk ratio
(95% CI)
Cut-off Comment
T regulatory cell/CD4+ lymphocyte
ratio
Adamzik
2013 [58]
Immunomodulation 47 6.5
(1.7–25)
≥ 7.4%
Biomarkers in urine
Desmosine-to-creatinine ratio McClintock
2006 [84]
Alveolar epithelial injury
(elastin breakdown)
579 1.36 (1.02–
1.82)
Per log10
Nitric oxide McClintock
2007 [85]
Oxidative injury 576 0.33 (0.20–
0.54)
Per log10
Nitric oxide-to-creatinine ratio McClintock
2007 [85]
Oxidative injury 576 0.43 (0.28–
0.66)
Per log10
Abbreviations: ALI acute lung injury, BALF bronchoalveolar lavage fluid, SD standard deviation
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This systematic review has limitations. First, the intent
of this systematic review was to perform a meta-analysis.
However, we decided not to perform a meta-analysis, as
the biomarker data handling and outcomes varied widely
among studies, and pooling would have resulted in a
non-informative estimate [21]. Arguably, this is a posi-
tive result, as it refrains us from focusing on the few bio-
markers that could be pooled in a meta-analysis and
guides us into a direction were multiple biomarkers
combined with other parameters are of interest. In a het-
erogeneous syndrome as ARDS, the one biomarker
probably does not exist. Second, the first sampling mo-
ment varied between sampling at ICU admission until
72 h following ICU admission. Initially, ARDS is charac-
terized by an exudative phase followed by a second pro-
liferative phase and late fibrotic phase [3]. The moment
of sampling likely influences biomarker concentrations,
as both alveolar membrane injury and inflammation in-
crease during the exudative phase. This is also seen in
six biomarkers that have been measured at separate
days, resulting in a significant change in adjusted OR for
four biomarkers (Table 4) [61, 98, 104, 105]. Third, the
aim of this systematic review was to assess the independ-
ent risk effects of biomarkers measured in various bodily
fluid compartments. However, the majority of studies
assessed biomarkers in plasma. It remains to be an-
swered whether other bodily fluid compartments, for ex-
ample from the airways and alveolar space themselves,
might outperform ARDS biomarkers in plasma, espe-
cially for ARDS development. Fourth, all studies found
in this systematic review used a clinical definition of
ARDS as standard for ARDS diagnosis. Given the poor
correlation between a clinical diagnosis and a histo-
pathological diagnosis of ARDS, these studies are diag-
nosing a very heterogeneous disease syndrome [7–10].
In order to actually evaluate ARDS development, bio-
markers should be compared to a histopathological
image of DAD, although acquiring histology poses great
challenges by itself. Fifth, as only biomarkers assessed in
multivariate analyses were included in this study, new
promising biomarkers evaluated in univariate analyses
were excluded from this study. Lastly, non-significant
biomarkers in multivariate analyses were more likely not
to be reported, although some studies report non-
significant results nonetheless.
Conclusion
In here, we present a list of biomarkers for ARDS mor-
tality and ARDS development tested in multivariate ana-
lyses. In multiple studies that assessed Ang-2 and RAGE,
high plasma levels were associated with an increased risk
of ARDS development. We did not find a biomarker that
independently predicted mortality in all studies that
assessed the biomarker. Furthermore, biomarker data
reporting and variables used in multivariate analyses dif-
fered greatly between studies. Taken together, we should
look for a combination of biomarkers and clinical pa-
rameters in a structured approach in order to find more
homogeneous ARDS phenotypes. This systematic review
may guide the selection of ARDS biomarkers for ARDS
phenotyping.
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